GlassScriptPhysician profile
Rodney E Vivian
NPI 1295763845
$5,597.58
in general payments reported to CMS, 2019-2025
28 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $707 · 2021: $1,164 · 2022: $1,265 · 2023: $994 · 2024: $588 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,698.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $769.95 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $706.52 | 2021-2025 | Vraylar |
| Ironshore Pharmaceuticals INC. | $666.41 | 2019-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $419.72 | 2019-2024 | Nuedexta, Rexulti |
| Lundbeck LLC | $305.20 | 2019-2025 | Rexulti |
| Allergan, INC. | $300.90 | 2019-2020 | |
| Alkermes, INC. | $295.63 | 2022-2023 | Aristada, Lybalvi |
| Corium, LLC | $278.11 | 2021-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $277.65 | 2019-2023 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $261.19 | 2020-2023 | Trintellix |
| Neos Therapeutics, LP | $217.93 | 2019-2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $214.78 | 2023-2025 | Xelstrym |
| Tris Pharma INC | $164.24 | 2019-2023 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $143.08 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $91.57 | 2020-2023 | Austedo Xr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.36 | 2021 | |
| Jazz Pharmaceuticals INC. | $74.18 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $68.34 | 2019-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $45.73 | 2022-2024 | Spravato |
| Merck Sharp & Dohme LLC | $45.37 | 2022-2023 | |
| Alfasigma USA, INC. | $37.63 | 2020-2021 | |
| Shire North American Group INC | $25.73 | 2019 | |
| Avanir Pharmaceuticals, INC. | $24.87 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.67 | 2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $16.21 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $14.99 | 2023 | Quviviq |
| Mdd US Operations, LLC | $13.98 | 2019 | |
| Almatica Pharma LLC | $13.64 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Vivian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.